New seizure drug tested in ICU for emergency seizure control

This early-phase study tests the drug cenobamate in 10 adults (ages 18–70) in the intensive care unit who are having frequent seizures or a prolonged seizure (status epilepticus). The goal is to see if cenobamate can quickly reach and maintain a target level in the blood, stop seizures within 24 hours, and reduce overall seizure burden. Participants will be closely monitored for side effects, including a rare but serious allergic reaction called DRESS syndrome.